Table 3.
Demographics and clinical data of study population, and medications prescribed after index PCI among groups.
| Variable | Study groups | P -value | |
|---|---|---|---|
| Smoker (N = 741) | Non-smoker (N = 1,303) | ||
| Gender | <0.01* | ||
| Female | 25 (3.4%) | 483 (37.1%) | |
| Male | 716 (96.6%) | 820 (62.9%) | |
| Hypertension | 0.74 | ||
| No | 331 (44.7%) | 592 (45.4%) | |
| Yes | 410 (55.3%) | 711 (54.6%) | |
| DM | <0.01* | ||
| No | 504 (68.0%) | 735 (56.4%) | |
| Yes | 237 (32.0%) | 568 (43.6%) | |
| Previous MI | <0.01* | ||
| No | 417 (56.3%) | 862 (66.2%) | |
| Yes | 324 (43.7%) | 441 (33.8%) | |
| CKD | <0.01* | ||
| No | 479 (64.6%) | 706 (54.2%) | |
| Yes | 262 (35.4%) | 597 (45.8%) | |
| Stroke history | 0.42 | ||
| No | 702 (94.7%) | 1,223 (93.9%) | |
| Yes | 39 (5.3%) | 80 (6.1%) | |
| CABG history | 0.12 | ||
| No | 739 (99.7%) | 1,292 (99.2%) | |
| Yes | 2 (0.3%) | 11 (0.8%) | |
| Aspirin | 0.37 | ||
| No | 66 (8.9%) | 132 (10.1%) | |
| Yes | 675 (91.1%) | 1,171 (89.9%) | |
| P2Y12 inhibitors | <0.01* | ||
| No | 90 (12.2%) | 216 (16.6%) | |
| Yes | 651 (87.8%) | 1,087 (83.4%) | |
| Diuretics | 0.23 | ||
| No | 602 (81.2%) | 1,030 (79.0%) | |
| Yes | 139 (18.8%) | 273 (21.0%) | |
| BB | <0.01* | ||
| No | 373 (50.3%) | 735 (56.4%) | |
| Yes | 368 (49.7%) | 568 (43.6%) | |
| CCB | 0.02 | ||
| No | 539 (72.7%) | 885 (67.9%) | |
| Yes | 202 (27.3%) | 418 (32.1%) | |
| ACEI | 0.31 | ||
| No | 594 (80.2%) | 1,068 (82.0%) | |
| Yes | 147 (19.8%) | 235 (18.0%) | |
| ARB | 0.30 | ||
| No | 535 (72.2%) | 968 (74.3%) | |
| Yes | 206 (27.8%) | 335 (25.7%) | |
| Statin | 0.04 | ||
| No | 426 (57.5%) | 809 (62.1%) | |
| Yes | 315 (42.5%) | 494 (37.9%) | |
| Fibrate | 0.07 | ||
| No | 692 (93.4%) | 1,244 (95.5%) | |
| Yes | 49 (6.6%) | 59 (4.5%) | |
DM, diabetes Mellitus; CKD, chronic kidney disease alone; Previous MI, history of previous myocardial infarction; CABG history, history of coronary artery bypass graft; CKD, chronic kidney disease; P2Y12 inhibitor: P2Y12 receptor inhibitor of platelet. BB, beta-blockers; CCB, calcium channel blocker; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.
*
significant.